Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Object Symbol | Species | Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | VGLL4 | Human | (1->4)-beta-D-glucan | multiple interactions | ISO | Vgll4 (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of VGLL4 mRNA | CTD | PMID:36331819 | VGLL4 | Human | 17alpha-ethynylestradiol | affects expression | ISO | Vgll4 (Mus musculus) | 6480464 | Ethinyl Estradiol affects the expression of VGLL4 mRNA | CTD | PMID:17555576 | VGLL4 | Human | 17alpha-ethynylestradiol | multiple interactions | ISO | Vgll4 (Mus musculus) | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of VGLL4 mRNA | CTD | PMID:17942748 | VGLL4 | Human | 17alpha-ethynylestradiol | increases expression | ISO | Vgll4 (Mus musculus) | 6480464 | Ethinyl Estradiol results in increased expression of VGLL4 mRNA | CTD | PMID:17942748 | VGLL4 | Human | 2,2',4,4'-Tetrabromodiphenyl ether | increases expression | ISO | Vgll4 (Rattus norvegicus) | 6480464 | 2 more ... | CTD | PMID:27291303 | VGLL4 | Human | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | Vgll4 (Mus musculus) | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of VGLL4 mRNA | CTD | PMID:17942748 | VGLL4 | Human | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | Vgll4 (Rattus norvegicus) | 6480464 | Tetrachlorodibenzodioxin affects the expression of VGLL4 mRNA | CTD | PMID:34747641 | VGLL4 | Human | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | Vgll4 (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of VGLL4 mRNA | CTD | PMID:26290441 | VGLL4 | Human | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | Vgll4 (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin affects the expression of VGLL4 mRNA | CTD | PMID:21570461 | VGLL4 | Human | 2-methylcholine | affects expression | EXP | | 6480464 | beta-methylcholine affects the expression of VGLL4 mRNA | CTD | PMID:21179406 | VGLL4 | Human | 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | EXP | | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of VGLL4 mRNA | CTD | PMID:28628672 | VGLL4 | Human | 4,4'-diaminodiphenylmethane | decreases expression | ISO | Vgll4 (Mus musculus) | 6480464 | 4 and 4'-diaminodiphenylmethane results in decreased expression of VGLL4 mRNA | CTD | PMID:18648102 | VGLL4 | Human | 4,4'-sulfonyldiphenol | multiple interactions | EXP | | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of VGLL4 mRNA | CTD | PMID:28628672 | VGLL4 | Human | 4,4'-sulfonyldiphenol | affects methylation | ISO | Vgll4 (Mus musculus) | 6480464 | bisphenol S affects the methylation of VGLL4 gene | CTD | PMID:31683443 | VGLL4 | Human | 4,4'-sulfonyldiphenol | decreases methylation | ISO | Vgll4 (Mus musculus) | 6480464 | bisphenol S results in decreased methylation of VGLL4 exon | CTD | PMID:33297965 | VGLL4 | Human | 4-hydroxyphenyl retinamide | increases expression | ISO | Vgll4 (Mus musculus) | 6480464 | Fenretinide results in increased expression of VGLL4 mRNA | CTD | PMID:28973697 | VGLL4 | Human | aflatoxin B1 | increases methylation | EXP | | 6480464 | Aflatoxin B1 results in increased methylation of VGLL4 gene and Aflatoxin B1 results in increased methylation of VGLL4 intron | CTD | PMID:27153756 and PMID:30157460 | VGLL4 | Human | Aflatoxin B2 alpha | increases methylation | EXP | | 6480464 | aflatoxin B2 results in increased methylation of VGLL4 intron | CTD | PMID:30157460 | VGLL4 | Human | amphetamine | decreases expression | ISO | Vgll4 (Rattus norvegicus) | 6480464 | Amphetamine results in decreased expression of VGLL4 mRNA | CTD | PMID:30779732 | VGLL4 | Human | antimycin A | decreases expression | EXP | | 6480464 | Antimycin A results in decreased expression of VGLL4 mRNA | CTD | PMID:33512557 | VGLL4 | Human | aristolochic acid A | decreases expression | EXP | | 6480464 | aristolochic acid I results in decreased expression of VGLL4 mRNA | CTD | PMID:33212167 | VGLL4 | Human | arsane | affects methylation | EXP | | 6480464 | Arsenic affects the methylation of VGLL4 gene | CTD | PMID:25304211 | VGLL4 | Human | arsenic atom | affects methylation | EXP | | 6480464 | Arsenic affects the methylation of VGLL4 gene | CTD | PMID:25304211 | VGLL4 | Human | arsenous acid | increases expression | EXP | | 6480464 | Arsenic Trioxide results in increased expression of VGLL4 mRNA | CTD | PMID:20458559 | VGLL4 | Human | atrazine | affects methylation | ISO | Vgll4 (Rattus norvegicus) | 6480464 | Atrazine affects the methylation of VGLL4 gene | CTD | PMID:35440735 | VGLL4 | Human | benzo[a]pyrene | decreases expression | EXP | | 6480464 | Benzo(a)pyrene results in decreased expression of VGLL4 mRNA | CTD | PMID:20064835 | VGLL4 | Human | benzo[a]pyrene | affects methylation | EXP | | 6480464 | Benzo(a)pyrene affects the methylation of VGLL4 intron | CTD | PMID:30157460 | VGLL4 | Human | benzo[a]pyrene | increases methylation | EXP | | 6480464 | Benzo(a)pyrene results in increased methylation of VGLL4 3' UTR | CTD | PMID:27901495 | VGLL4 | Human | benzo[a]pyrene | multiple interactions | ISO | Vgll4 (Mus musculus) | 6480464 | AHR protein affects the reaction [Benzo(a)pyrene affects the expression of VGLL4 mRNA] | CTD | PMID:22228805 | VGLL4 | Human | benzo[e]pyrene | decreases methylation | EXP | | 6480464 | benzo(e)pyrene results in decreased methylation of VGLL4 intron | CTD | PMID:30157460 | VGLL4 | Human | bisphenol A | increases expression | ISO | Vgll4 (Rattus norvegicus) | 6480464 | bisphenol A results in increased expression of VGLL4 mRNA | CTD | PMID:25181051 | VGLL4 | Human | bisphenol A | decreases methylation | EXP | | 6480464 | bisphenol A results in decreased methylation of VGLL4 gene | CTD | PMID:31601247 | VGLL4 | Human | bisphenol A | decreases expression | ISO | Vgll4 (Rattus norvegicus) | 6480464 | bisphenol A results in decreased expression of VGLL4 mRNA | CTD | PMID:30816183 | VGLL4 | Human | bisphenol A | increases methylation | ISO | Vgll4 (Rattus norvegicus) | 6480464 | bisphenol A results in increased methylation of VGLL4 gene | CTD | PMID:28505145 | VGLL4 | Human | bisphenol F | increases expression | ISO | Vgll4 (Mus musculus) | 6480464 | bisphenol F results in increased expression of VGLL4 mRNA | CTD | PMID:38685157 | VGLL4 | Human | cadmium atom | multiple interactions | EXP | | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of VGLL4 mRNA | CTD | PMID:35301059 | VGLL4 | Human | cadmium dichloride | multiple interactions | EXP | | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of VGLL4 mRNA | CTD | PMID:35301059 | VGLL4 | Human | caffeine | affects phosphorylation | EXP | | 6480464 | Caffeine affects the phosphorylation of VGLL4 protein | CTD | PMID:35688186 | VGLL4 | Human | calcitriol | increases expression | EXP | | 6480464 | Calcitriol results in increased expression of VGLL4 mRNA | CTD | PMID:16002434 | VGLL4 | Human | carbon nanotube | decreases expression | ISO | Vgll4 (Mus musculus) | 6480464 | Nanotubes and Carbon analog results in decreased expression of VGLL4 mRNA | CTD | PMID:25620056 | VGLL4 | Human | chloroprene | decreases expression | ISO | Vgll4 (Rattus norvegicus) | 6480464 | Chloroprene results in decreased expression of VGLL4 mRNA | CTD | PMID:23125180 | VGLL4 | Human | cobalt dichloride | increases expression | EXP | | 6480464 | cobaltous chloride results in increased expression of VGLL4 mRNA | CTD | PMID:19376846 | VGLL4 | Human | copper atom | increases expression | ISO | Vgll4 (Rattus norvegicus) | 6480464 | Copper results in increased expression of VGLL4 mRNA | CTD | PMID:30556269 | VGLL4 | Human | copper(0) | increases expression | ISO | Vgll4 (Rattus norvegicus) | 6480464 | Copper results in increased expression of VGLL4 mRNA | CTD | PMID:30556269 | VGLL4 | Human | coumarin | decreases phosphorylation | EXP | | 6480464 | coumarin results in decreased phosphorylation of VGLL4 protein | CTD | PMID:35688186 | VGLL4 | Human | coumestrol | decreases expression | EXP | | 6480464 | Coumestrol results in decreased expression of VGLL4 mRNA | CTD | PMID:19167446 | VGLL4 | Human | cyclosporin A | increases expression | EXP | | 6480464 | Cyclosporine results in increased expression of VGLL4 mRNA | CTD | PMID:20106945 | VGLL4 | Human | cyclosporin A | decreases expression | EXP | | 6480464 | Cyclosporine results in decreased expression of VGLL4 mRNA | CTD | PMID:25562108 | VGLL4 | Human | cytarabine | decreases expression | EXP | | 6480464 | Cytarabine results in decreased expression of VGLL4 mRNA | CTD | PMID:21198554 | VGLL4 | Human | dexamethasone | multiple interactions | EXP | | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of VGLL4 mRNA | CTD | PMID:28628672 | VGLL4 | Human | diarsenic trioxide | increases expression | EXP | | 6480464 | Arsenic Trioxide results in increased expression of VGLL4 mRNA | CTD | PMID:20458559 | VGLL4 | Human | dibutyl phthalate | increases expression | ISO | Vgll4 (Rattus norvegicus) | 6480464 | Dibutyl Phthalate results in increased expression of VGLL4 mRNA | CTD | PMID:21266533 | VGLL4 | Human | doxorubicin | decreases expression | EXP | | 6480464 | Doxorubicin results in decreased expression of VGLL4 mRNA | CTD | PMID:29803840 | VGLL4 | Human | endosulfan | decreases expression | ISO | Vgll4 (Rattus norvegicus) | 6480464 | Endosulfan results in decreased expression of VGLL4 mRNA | CTD | PMID:29391264 | VGLL4 | Human | ethanol | multiple interactions | EXP | | 6480464 | [[Gasoline co-treated with Ethanol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of VGLL4 mRNA | CTD | PMID:29432896 | VGLL4 | Human | ethanol | affects expression | ISO | Vgll4 (Mus musculus) | 6480464 | Ethanol affects the expression of VGLL4 mRNA | CTD | PMID:30319688 | VGLL4 | Human | ethanol | affects splicing | ISO | Vgll4 (Mus musculus) | 6480464 | Ethanol affects the splicing of VGLL4 mRNA | CTD | PMID:30319688 | VGLL4 | Human | fenpyroximate | decreases expression | EXP | | 6480464 | fenpyroximate results in decreased expression of VGLL4 mRNA | CTD | PMID:33512557 | VGLL4 | Human | fenthion | increases expression | ISO | Vgll4 (Mus musculus) | 6480464 | Fenthion results in increased expression of VGLL4 mRNA | CTD | PMID:34813904 | VGLL4 | Human | FR900359 | decreases phosphorylation | EXP | | 6480464 | FR900359 results in decreased phosphorylation of VGLL4 protein | CTD | PMID:37730182 | VGLL4 | Human | fulvestrant | decreases methylation | EXP | | 6480464 | Fulvestrant results in decreased methylation of VGLL4 gene | CTD | PMID:31601247 | VGLL4 | Human | furan | decreases expression | ISO | Vgll4 (Rattus norvegicus) | 6480464 | furan results in decreased expression of VGLL4 mRNA | CTD | PMID:26194646 | VGLL4 | Human | indometacin | multiple interactions | EXP | | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of VGLL4 mRNA | CTD | PMID:28628672 | VGLL4 | Human | inulin | multiple interactions | ISO | Vgll4 (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Inulin] results in decreased expression of VGLL4 mRNA | CTD | PMID:36331819 | VGLL4 | Human | ketoconazole | decreases expression | EXP | | 6480464 | Ketoconazole results in decreased expression of VGLL4 mRNA | CTD | PMID:36621641 | VGLL4 | Human | menadione | affects expression | EXP | | 6480464 | Vitamin K 3 affects the expression of VGLL4 mRNA | CTD | PMID:20044591 | VGLL4 | Human | metformin | decreases expression | ISO | Vgll4 (Rattus norvegicus) | 6480464 | Metformin results in decreased expression of VGLL4 mRNA | CTD | PMID:31324951 | VGLL4 | Human | methapyrilene | decreases methylation | EXP | | 6480464 | Methapyrilene results in decreased methylation of VGLL4 intron | CTD | PMID:30157460 | VGLL4 | Human | methoxychlor | affects methylation | ISO | Vgll4 (Rattus norvegicus) | 6480464 | Methoxychlor affects the methylation of VGLL4 gene | CTD | PMID:35440735 | VGLL4 | Human | methyl methanesulfonate | decreases expression | EXP | | 6480464 | Methyl Methanesulfonate results in decreased expression of VGLL4 mRNA | CTD | PMID:23649840 | VGLL4 | Human | ozone | multiple interactions | ISO | Vgll4 (Mus musculus) | 6480464 | [Air Pollutants results in increased abundance of [Ozone co-treated with Soot]] which results in decreased expression of VGLL4 mRNA | CTD | PMID:34911549 | VGLL4 | Human | paracetamol | increases expression | EXP | | 6480464 | Acetaminophen results in increased expression of VGLL4 mRNA | CTD | PMID:29067470 | VGLL4 | Human | paracetamol | decreases expression | ISO | Vgll4 (Rattus norvegicus) | 6480464 | Acetaminophen results in decreased expression of VGLL4 mRNA | CTD | PMID:33387578 | VGLL4 | Human | perfluorooctane-1-sulfonic acid | multiple interactions | ISO | Vgll4 (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of VGLL4 mRNA and [perfluorooctane sulfonic acid co-treated with Inulin] results in decreased expression of VGLL4 mRNA | CTD | PMID:36331819 | VGLL4 | Human | phenformin | decreases expression | ISO | Vgll4 (Rattus norvegicus) | 6480464 | Phenformin results in decreased expression of VGLL4 mRNA | CTD | PMID:31324951 | VGLL4 | Human | phenobarbital | affects expression | ISO | Vgll4 (Mus musculus) | 6480464 | Phenobarbital affects the expression of VGLL4 mRNA | CTD | PMID:23091169 | VGLL4 | Human | pirinixic acid | multiple interactions | ISO | Vgll4 (Mus musculus) | 6480464 | [pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of VGLL4 mRNA | CTD | PMID:19710929 | VGLL4 | Human | silver atom | decreases expression | ISO | Vgll4 (Mus musculus) | 6480464 | Silver results in decreased expression of VGLL4 mRNA | CTD | PMID:27131904 | VGLL4 | Human | silver(0) | decreases expression | ISO | Vgll4 (Mus musculus) | 6480464 | Silver results in decreased expression of VGLL4 mRNA | CTD | PMID:27131904 | VGLL4 | Human | sodium arsenite | decreases expression | ISO | Vgll4 (Mus musculus) | 6480464 | sodium arsenite results in decreased expression of VGLL4 mRNA | CTD | PMID:37682722 | VGLL4 | Human | sunitinib | decreases expression | EXP | | 6480464 | Sunitinib results in decreased expression of VGLL4 mRNA | CTD | PMID:31533062 | VGLL4 | Human | tamoxifen | affects expression | ISO | Vgll4 (Mus musculus) | 6480464 | Tamoxifen affects the expression of VGLL4 mRNA | CTD | PMID:17555576 | VGLL4 | Human | tebufenpyrad | decreases expression | EXP | | 6480464 | 4-chloro-N-((4-(1 and 1-dimethylethyl)phenyl)methyl)-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide results in decreased expression of VGLL4 mRNA | CTD | PMID:33512557 | VGLL4 | Human | tert-butyl hydroperoxide | decreases expression | EXP | | 6480464 | tert-Butylhydroperoxide results in decreased expression of VGLL4 mRNA | CTD | PMID:15336504 | VGLL4 | Human | trichloroethene | increases expression | ISO | Vgll4 (Rattus norvegicus) | 6480464 | Trichloroethylene results in increased expression of VGLL4 mRNA | CTD | PMID:33387578 | VGLL4 | Human | triphenyl phosphate | affects expression | EXP | | 6480464 | triphenyl phosphate affects the expression of VGLL4 mRNA | CTD | PMID:37042841 | VGLL4 | Human | tunicamycin | increases expression | EXP | | 6480464 | Tunicamycin results in increased expression of VGLL4 mRNA | CTD | PMID:29453283 | VGLL4 | Human | valproic acid | affects expression | EXP | | 6480464 | Valproic Acid affects the expression of VGLL4 mRNA | CTD | PMID:25979313 | VGLL4 | Human | vitamin E | decreases expression | EXP | | 6480464 | Vitamin E results in decreased expression of VGLL4 mRNA | CTD | PMID:19244175 | |